Latrepirdine (Dimebon®), a potential Alzheimer therapeutic, regulates autophagy and neuropathology in an Alzheimer mouse model

Steele, John W.; Gandy, Sam
April 2013
Autophagy;Apr2013, Vol. 9 Issue 4, p617
Academic Journal
No abstract available.


Related Articles

  • Latrepirdine stimulates autophagy and reduces accumulation of α-synuclein in cells and in mouse brain. Steele, J W; Ju, S; Lachenmayer, M L; Liken, J; Stock, A; Kim, S H; Delgado, L M; Alfaro, I E; Bernales, S; Verdile, G; Bharadwaj, P; Gupta, V; Barr, R; Friss, A; Dolios, G; Wang, R; Ringe, D; Protter, A A; Martins, R N; Ehrlich, M E // Molecular Psychiatry;Aug2013, Vol. 18 Issue 8, p882 

    Latrepirdine (Dimebon; dimebolin) is a neuroactive compound that was associated with enhanced cognition, neuroprotection and neurogenesis in laboratory animals, and has entered phase II clinical trials for both Alzheimer's disease and Huntington's disease (HD). Based on recent indications that...

  • Latrepirdine improves cognition and arrests progression of neuropathology in an Alzheimer's mouse model. Steele, J W; Lachenmayer, M L; Ju, S; Stock, A; Liken, J; Kim, S H; Delgado, L M; Alfaro, I E; Bernales, S; Verdile, G; Bharadwaj, P; Gupta, V; Barr, R; Friss, A; Dolios, G; Wang, R; Ringe, D; Fraser, P; Westaway, D; St George-Hyslop, P H // Molecular Psychiatry;Aug2013, Vol. 18 Issue 8, p889 

    Latrepirdine (Dimebon) is a pro-neurogenic, antihistaminic compound that has yielded mixed results in clinical trials of mild to moderate Alzheimer's disease, with a dramatically positive outcome in a Russian clinical trial that was unconfirmed in a replication trial in the United States. We...

  • Plaques, Tangles, and Memory Loss in Mouse Models of Neurodegeneration. Eriksen, Jason L.; Janus, Christopher G. // Behavior Genetics;Jan2007, Vol. 37 Issue 1, p79 

    Within the past decade, our understanding of the pathogenic mechanisms in Alzheimer’s disease (AD) has dramatically advanced because of the development of transgenic mouse models that recapitulate the key pathological and behavioral phenotypes of the disease. These mouse models have...

  • Dimebon alters hippocampal amyloid pathology in 3xTg-AD mice. Perez, Sylvia E.; Nadeem, Muhammad; Sadleir, Katherine R.; Matras, Joanna; Kelley, Christy M.; Counts, Scott E.; Vassar, Robert; Mufson, Elliott J. // International Journal of Physiology, Pathophysiology & Pharmacol;2012, Vol. 4 Issue 3, p115 

    A double blind, placebo-controlled phase II study revealed that the antihistamine, Dimebon(r) (dimebolin, latrepirdine) improved cognition in Alzheimer disease (AD) patients compared to placebo controls. However, the Phase III CONNECTION trial failed to demonstrate significant differences...

  • Dimebon Dropped Following Phase III Huntington's Failure. Wall, Tom // BioWorld Today;4/12/2011, Vol. 22 Issue 70, p2 

    The article reports that Medivation Inc. of San Francisco, California and partner Pfizer Inc. of New York will halt the development of its dimebon (latrepirdine) drug in Huntington's disease after the Phase III Horizon trial showed that the drug did not meet the primary efficacy endpoints in...

  • Wnt signaling activation reduces neuropathological markers in a mouse model of Alzheimer's disease. Toledo, E. M.; Inestrosa, N. C. // Molecular Psychiatry;Mar2010, Vol. 15 Issue 3, p228 

    An image of Wnt signaling activation of neuropathological markers in a mouse model of Alzheimer's disease, is presented.

  • Preclinical study of dimebon on β-amyloid-mediated neuropathology in Alzheimer's disease. Jun Wang; Ferruzzi, Mario G.; Varghese, Merina; Xianjuan Qian; Alice Cheng; Mathew Xie; Wei Zhao; Lap Ho; Pasinetti, Giulio M. // Molecular Neurodegeneration;2011, Vol. 6 Issue 1, p7 

    Background: Dimebon is a retired non-selective antihistamine drug currently being investigated as a therapeutic agent for the treatment of Alzheimer's disease (AD). Results from several completed clinical trials are mixed and contradictory. Proper interpretations of these clinical observations,...

  • Dimebon disappointment. Jones, Roy W. // Alzheimer's Research & Therapy;2010, Vol. 2 Issue 5, p1 

    Dimebon (latrepirdine) has received widespread publicity as a potential therapy for Alzheimer's disease following a very positive phase 2 study carried out in Russia and published in the Lancet in 2008. In this study there were improvements over 6 months in all endpoints (cognitive, global,...

  • Phase III CONCERT Trial of Latrepirdine. Sweetlove, Mel // Pharmaceutical Medicine - New Zealand;2012, Vol. 26 Issue 2, p113 

    CONCERT: a Phase III multicentre randomized, placebo-controlled, double-blind 12-month safety and efficacy study evaluating dimebon in patients with mild-to-moderate Alzheimer's disease on donepezil. This trial investigated the efficacy and tolerability of adjunctive therapy with latrepirdine at...

  • Dimebon Bust 'No Surprise': Back to Drawing Board in AD. Osborne, Randy // BioWorld Insight;3/15/2010, Vol. 18 Issue 11, p1 

    The article reports on the failure in the phase III trial of biotech firm Medivation Inc.'s Dimebon (latrepirdine) for Alzheimer's disease (AD). It states that the failure threatened the firm's deal with pharmaceutical firm Pfizer Inc. and triggered shareholder lawsuits and raised the stakes for...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics